{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:10:11Z","timestamp":1760044211244,"version":"3.37.3"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["R01 DA042790"],"award-info":[{"award-number":["R01 DA042790"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Health Resources and Services Administration","award":["UD9RH33633"],"award-info":[{"award-number":["UD9RH33633"]}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["P20GM103644"],"award-info":[{"award-number":["P20GM103644"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ypmed.2019.105818","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:24:06Z","timestamp":1566404646000},"page":"105818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Innovations in efforts to expand treatment for opioid use disorder"],"prefix":"10.1016","volume":"128","author":[{"given":"Stacey C.","family":"Sigmon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2019.105818_bb0005","doi-asserted-by":"crossref","DOI":"10.1080\/08897077.2018.1443541","article-title":"Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program","author":"Bachhuber","year":"2018","journal-title":"Subst. Abus."},{"issue":"4","key":"10.1016\/j.ypmed.2019.105818_bb0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/ADM.0000000000000400","article-title":"Gaps in the substance use disorder treatment referral process: provider perceptions","volume":"12","author":"Blevins","year":"2018","journal-title":"J. Addict. Med."},{"issue":"4","key":"10.1016\/j.ypmed.2019.105818_bb0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorders: development, implementation and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J. Addict. Med."},{"issue":"16","key":"10.1016\/j.ypmed.2019.105818_bb0020","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ypmed.2019.105818_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2019.105818_bb0030","series-title":"Putting Parity into Practice \u2013 Integrating Opioid-use Disorder Treatment Into the Hospital Setting","volume":"1","author":"Fanucchi","year":"2016"},{"key":"10.1016\/j.ypmed.2019.105818_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2019.105818_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.ypmed.2019.105818_bb0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/add.14545","article-title":"Buprenorphine and the glass half full- why can\u2019t we prescribe more of it, and will nurse practitioners and physician assistants fulfill a chronic unmet need?","volume":"114","author":"Lee","year":"2019","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.ypmed.2019.105818_bb0050","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.ypmed.2019.105818_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JCP.0000000000000434","article-title":"Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"year":"2013","series-title":"2011 Data Submission","author":"National Cancer Database, American College of Surgeons Commission on Cancer","key":"10.1016\/j.ypmed.2019.105818_bb0060"},{"key":"10.1016\/j.ypmed.2019.105818_bb0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/ADM.0b013e318287cfc9","article-title":"Opiate-dependent patients on a waiting list for methadone maintenance treatment are at high risk for mortality until treatment entry","volume":"7","author":"Peles","year":"2013","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.ypmed.2019.105818_bb0070","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jsat.2018.11.003","article-title":"Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system","volume":"97","author":"Rawson","year":"2019","journal-title":"J. Subst. Abus. Treat."},{"issue":"3","key":"10.1016\/j.ypmed.2019.105818_bb0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ypmed.2019.105818_bb0080","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","article-title":"Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004-2013","volume":"314","author":"Saloner","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ypmed.2019.105818_bb0085","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/add.13539","article-title":"Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential","volume":"112","author":"Sigmon","year":"2017","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.ypmed.2019.105818_bb0090","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1360-0443.2004.00834.x","article-title":"Evaluation of an injection depot formulation of buprenorphine: placebo comparison","volume":"99","author":"Sigmon","year":"2004","journal-title":"Addiction"},{"issue":"25","key":"10.1016\/j.ypmed.2019.105818_bb0095","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1610047","article-title":"Interim buprenorphine vs waiting list for opioid dependence","volume":"375","author":"Sigmon","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ypmed.2019.105818_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1037\/pha0000199","article-title":"Interim buprenorphine treatment during delays to comprehensive treatment: changes in psychiatric symptoms","volume":"26","author":"Streck","year":"2018","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.ypmed.2019.105818_bb0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/jwh.2008.1127","article-title":"The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review","volume":"18","author":"Vona-Davis","year":"2009","journal-title":"J. Women\u2019s Health"},{"key":"10.1016\/j.ypmed.2019.105818_bb0110","series-title":"Expanding Access to Buprenorphine Treatment in Rural Areas With the Use of Telemedicine","first-page":"612","volume":"27(8)","author":"Weintraub","year":"2018"}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519302944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519302944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T17:12:17Z","timestamp":1574442737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743519302944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":22,"alternative-id":["S0091743519302944"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.105818","relation":{},"ISSN":["0091-7435"],"issn-type":[{"type":"print","value":"0091-7435"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovations in efforts to expand treatment for opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.105818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105818"}}